文献速递白血病

可测量残留病与融合伴侣独立预测儿童KMT2A重排急性髓系白血病的生存与复发风险:国际柏林-法兰克福-明斯特研究组的一项研究

Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
PubMed 文献 · J Clin Oncol · 2023-03-30

该国际柏林-法兰克福-明斯特研究组研究纳入2005年1月至2016年12月诊断的1130例儿童KMT2A重排急性髓系白血病,按融合伴侣分为高危组(402例,35.6%)和非高危组(728例,64.4%)。456例有诱导1结束(EOI1)和诱导2结束(EOI2)的流式MRD数据,以<0.1%为阴性、≥0.1%为阳性。EOI2流式MRD是独立预后因素,应纳入儿童KMT2A重排急性髓系白血病的风险分层;高危组首次完全缓解(CR1)期异基因造血干细胞移植(allo-SCT)仅降低累积复发率(CIR),未改善总生存(OS)。

要点

  • 高危融合伴侣组5年无事件生存(EFS)30.3% vs 非高危组54.0%,CIR 59.7% vs 35.2%,OS 49.2% vs 70.5%。
  • EOI2 MRD阴性组EFS 47.6% vs 阳性组16.3%,OS 66.0% vs 27.9%,CIR 46.1% vs 65.4%(P=0.016)。
  • 高危组CR1期allo-SCT仅降低CIR(HR 0.5,95%CI 0.4-0.8;P=0.00096),未改善OS。

核心结论

  • EOI2流式MRD是独立预后因素,应作为儿童KMT2A重排急性髓系白血病的风险分层因素。
  • 需要allo-SCT以外的治疗策略来改善预后。

研究设计与样本

  • 国际柏林-法兰克福-明斯特研究组(I-BFM-SG)研究,纳入2005年1月至2016年12月诊断的1130例儿童KMT2A重排急性髓系白血病。
  • 按融合伴侣分为高危组(n=402;35.6%)和非高危组(n=728;64.4%)。
  • 456例患者有EOI1和EOI2的流式MRD数据,以<0.1%为阴性、≥0.1%为阳性。
  • 终点为5年无事件生存(EFS)、累积复发率(CIR)和总生存(OS)。

主要发现

  • 高危组EFS 30.3% vs 非高危组54.0%(P<0.0001),CIR 59.7% vs 35.2%(P<0.0001),OS 49.2% vs 70.5%(P<0.0001)。
  • EOI2 MRD阴性组(n=413)EFS 47.6% vs 阳性组(n=43)16.3%(P<0.0001),OS 66.0% vs 27.9%(P<0.0001)。
  • EOI2 MRD阴性组(n=392)CIR 46.1% vs 阳性组(n=26)65.4%(P=0.016)。
  • 在高危组和非高危组内,EOI2 MRD阴性均与更优EFS和OS相关,但非高危组内MRD阴性者CIR与MRD阳性者相当。
  • 高危组CR1期allo-SCT仅降低CIR(HR 0.5,95%CI 0.4-0.8;P=0.00096),未改善OS。

关键数值与推荐

  • 流式MRD阴性定义为<0.1%,阳性定义为≥0.1%。
  • 高危融合伴侣组5年EFS 30.3%、CIR 59.7%、OS 49.2%;非高危组分别为54.0%、35.2%、70.5%。
  • EOI2 MRD阴性组5年EFS 47.6%、OS 66.0%、CIR 46.1%;阳性组分别为16.3%、27.9%、65.4%。

临床怎么用

  • 作者认为EOI2流式MRD应作为儿童KMT2A重排急性髓系白血病的风险分层因素。
  • 作者指出需要allo-SCT以外的治疗策略来改善预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease. METHODS: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS). RESULTS: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS. CONCLUSION: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. van Weelderen RE, Klein K, Harrison CJ, et al. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2023. PMID: 36996387. doi:10.1200/JCO.22.02120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。